Dermavant Sciences, a Phase 3 biotech developing in-licensed therapies for dermatological diseases, postponed its IPO on Thursday. It had filed to raise $100 million by offering 7.7 million shares at a price range of $12 to $14.
The Phoenix, AZ-based company was founded in 2015 and had planned to list on the Nasdaq under the symbol DRMT. Jefferies, SVB Leerink and Guggenheim Securities were set to be the joint bookrunners on the deal.
